Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cynosure, Inc. Receives FDA 510(k) Clearance for Cellulaze Cellulite Laser Workstation
Cynosure, Inc. announced that the U.S. Food and Drug Administration has cleared the Company's Cellulaze Workstation for commercial distribution, giving millions of American women the first minimally invasive solution in their battle against cellulite.
Latest Developments for Cynosure Inc
Latest Key Developments in Advanced
- Edap Tms SA Receives CE Mark For Focal.one
- Andor Technology plc Issues FY 2013 Revenue Guidance Below Analysts' Estimates-DJ
- Boston Scientific Corp's Vercise DBS System Demonstrates Improvement In Motor Function For Patients With Parkinson's Disease
- USCOM Ltd Completes Pulsecor Asset Purchase and Acquires New BP+ Central Blood Pressure Device
- Share this
- Link this
- Digg this
Follow Reuters